A photo of Patrick McGann.

Member, Division of Hematology

Associate Professor, UC Department of Pediatrics



Board Certified

My Biography & Research


Dr. McGann is an academic pediatric hematologist with research focusing on improving outcomes for children with sickle cell anemia, both in the United States and across the world. His work globally has included time living in Angola to lead the Angola Sickle Cell Initiative, which implemented the country’s first newborn screening program for sickle cell anemia. His current research efforts include both laboratory-based efforts here in the United States focused on the pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea, as well as clinical research efforts to improve the diagnosis and outcomes for children with sickle cell anemia living in sub-Saharan Africa.

He is also actively involved in global hematology and global child health through such organizations as the Global Sickle Cell Disease Network, the Central African Sickle Cell Network (REDAC), the American Society of Hematology, and the AAP's Section on International Child Health (SOICH).

Additional Languages


Academic Affiliation

Associate Professor, UC Department of Pediatrics


Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders, Hematology, Cancer and Blood Diseases, Global Health

Blog Posts

Cincinnati Children’s Launches 6 COVID-19 Research Projects

Infectious Diseases and Vaccines

Cincinnati Children’s Launches 6 COVID-19 Research Projects

Patrick T. McGann, MD, MS, Ming Tan, PhD ...5/26/2020

Our 2019 Research Annual Report

Genomics and Development

Our 2019 Research Annual Report

Patrick T. McGann, MD, MS, John Hogenesch, PhD ...2/4/2020

My Locations

My Education

MD: Tufts University School of Medicine, Boston, MA, 2006.

Residency: Pediatrics, Massachusetts General Hospital, Boston, MA, 2009.

Fellowship: Pediatric Hematology-Oncology, St. Jude Children's Research Hospital, 2009-2011; Baylor College of Medicine, 2011-2012.

MS: Clinical Research, Baylor College of Medicine, 2013.

Board Certification: Pediatrics, 2009; Pediatric Hematology-Oncology, 2013.

My Publications

End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings. Farrell, AT; Panepinto, J; Desai, AA; Kassim, AA; Lebensburger, J; Walters, MC; Bauer, DE; Blaylark, RM; DiMichele, DM; Gladwin, MT; et al. Blood Advances. 2019; 3:4002-4020.

Hydroxyurea for children with sickle cell anemia: Prescribe it early and often. Ware, RE; McGann, PT; Quinn, CT. Pediatric Blood and Cancer. 2019; 66.

Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. American Journal of Hematology. 2019; 94:871-879.

Non–transfusion-dependent β-Thalassemia Because of a Single β-Thalassemia Mutation and Coinherited α-Globin Gene Triplication. Gurunathan, A; Tarango, C; McGann, PT; Niss, O; Quinn, CT. Journal of Pediatric Hematology/Oncology. 2019; Publish Ahead of Print.

Hereditary elliptocytosis-associated alpha-spectrin mutation p.L155dup as a modifier of sickle cell disease severity. Risinger, M; Christakopoulos, GE; Schultz, CL; McGann, PT; Zhang, W; Kalfa, TA. Pediatric Blood and Cancer. 2019; 66:e27531-e27531.

Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. Santos, B; Bernardino, L; Luis, J; da Fonseca, R; Nassesa, L; Andre, DA D O; Cuhna, L; Bengui, AF; de Oliveira, V; Tshilolo, L; et al. The New England journal of medicine. 2019; 380:121-131.

Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children. McGann, PT; Williams, AM; Ellis, G; McElhinney, KE; Romano, L; Woodall, J; Howard, TA; Tegha, G; Krysiak, R; Lark, RM; et al. Blood Advances. 2018; 2:3035-3044.

Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. McGann, PT; Williams, TN; Olupot-Olupot, P; Tomlinson, GA; Lane, A; Reis da Fonseca, JL; Kitenge, R; Mochamah, G; Wabwire, H; Stuber, S; et al. American Journal of Hematology. 2018; 93:537-545.

Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. Dong, M; McGann, PT; Mizuno, T; Ware, RE; Vinks, AA. British Journal of Clinical Pharmacology. 2018; 84:1410-1412.

The Collaborative Role of North American Departments of Pediatrics in Global Child Health. Gladding, SP; McGann, PT; Summer, A; Russ, CM; Uwemedimo, OT; Aguilar, MM; Chakraborty, R; Moore, M; Lieh-Lai, M; Opoka, R; et al. Pediatrics. 2018; 142:e20172966-e20172966.